Marker Therapeutics, Inc. (MRKR), Thursday announced an update from its APOLLO study investigating MT-601 in patients with relapsed lymphoma.
The company found that 78 percent of patients achieved objective response rates, with 44.4 percent demonstrating complete response. Moreover, MT-601 was well tolerated with no observation of immune-effector cell associated neurotoxicity syndrome.
Concurrently with the update, Marker also announced the decision to sell around 5.03 million shares at $3.20 a share to raise $16.1 million in private placement.
The company intends to use the proceeds to fund Phase 1 APOLLO study.
Currently, Marker's stock is trading at $3.96, down 1.63 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com